This is to inform that Ms. Gowree Gokhale (DIN: 09351661) has been appointed as an Additional Director (designated as non-executive and Independent Director) w.e.f. April 01, 2026, for ....
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India's board has appointed Ms. Gowree Gokhale (DIN: 09351661) as an Additional Director designated as Non-Executive and Independent Director for a 5-year term from April 1, 2026 to March 31, 2031, subject to shareholder approval via postal ballot. Ms. Gokhale is a senior solicitor with 30+ years of legal experience in intellectual property, pharma regulation, data protection, and competition law, and was formerly with Nishith Desai Associates for 22 years. In a related change, Ms. Sandra Martyres (DIN: 00798406) will complete her second and final term as Independent Director and cease to be a director from close of business on April 18, 2026. The board placed on record its appreciation for Ms. Martyres' contributions. A postal ballot notice has been approved to seek members' approval for Ms. Gokhale's appointment.
This is a routine board refresh with no change in management, control, or strategy. Adding a legal and IP expert could be seen as relevant for a pharma-major, but no material impact on operations or share price is expected. Shareholders will get to vote on the new appointment through a postal ballot.